Please see the first issue of OIS Press with updates on novel ophthalmic therapies. I provide a perspective in recent US FDA approvals (Pages 9 and 11).
in 2016, the European Medicines Agency Committee for Medicinal Products for Human Use (CHMP) recommended 81 medicines for marketing authorization. Of these 27 were “new active substances” and 17 had an orphan designation. There were 2 negative opinions, which later went on to receive a positive opinion. None of the approvals were for ophthalmic products.